▪
|
Reported net sales of $1.3 billion increased 12% compared to second quarter 2017.
|
▪
|
Local currency net sales growth in all six regions.
|
▪
|
Volume points of 1.5 billion, the highest amount to be recorded in a quarter in Company history, increased 12% compared to the prior year period, above the guidance range of 4.0%– 8.0%.
|
▪
|
Reported diluted EPS of $0.62 and adjusted1 earnings of $0.80 per adjusted2 diluted share, compared to $0.81 and $0.76, respectively, for the second quarter last year.
|
▪
|
Raising FY 2018 volume point guidance range to 6.0% - 9.0% growth, as well as updating reported and adjusted1 diluted EPS guidance to $1.95 - $2.15 and $2.60 – $2.80, respectively.
|
“Our top-line growth
rate accelerated in
the second quarter
reflecting the
strength of our
business model to
provide solutions to
many of today’s
global nutrition
and wellness
megatrends.”
-Rich Goudis, CEO of
Herbalife Nutrition
|
|
Volume Points
|
|
Region
|
2Q '18 (mil)
|
Yr/Yr % Chg
|
North America
|
336.4
|
18.4%
|
EMEA
|
319.5
|
12.7%
|
Asia Pacific
|
302.8
|
9.7%
|
Mexico
|
237.1
|
3.6%
|
China
|
196.1
|
27.4%
|
South & Central America
|
136.3
|
(0.9%)
|
Worldwide Total (a)
|
1,528.2
|
12.0%
|
Region
|
Reported Net Sales
2Q’18 (mil)
|
Growth/Decline
including FX
vs. 2Q ‘17
|
Growth/Decline
excluding FX
vs. 2Q ‘17
|
|||||||||
North America
|
$
|
262.5
|
20.2
|
%
|
20.0
|
%
|
||||||
EMEA
|
$
|
260.0
|
15.7
|
%
|
12.4
|
%
|
||||||
Asia Pacific
|
$
|
253.0
|
7.4
|
%
|
7.4
|
%
|
||||||
Mexico
|
$
|
118.2
|
2.2
|
%
|
6.7
|
%
|
||||||
China
|
$
|
286.8
|
18.2
|
%
|
9.8
|
%
|
||||||
South & Central America (a)
|
$
|
105.0
|
(4.5
|
%)
|
183.1
|
%
|
||||||
Worldwide Total
|
$
|
1,285.5
|
12.1
|
%
|
28.1
|
%
|
||||||
South & Central America excl. Venezuela (a)
|
$
|
102.2
|
(5.5
|
%)
|
0.3
|
%
|
||||||
Worldwide Total excl. Venezuela (a)
|
$
|
1,282.7
|
12.0
|
%
|
10.6
|
%
|
Three Months Ending
|
Twelve Months Ending
|
|||||||||||||||
September 30, 2018
|
December 31, 2018
|
|||||||||||||||
Low
|
High
|
Low
|
High
|
|||||||||||||
Volume Point Growth vs 2017 (a)
|
8.5
|
%
|
12.5
|
%
|
6.0
|
%
|
9.0
|
%
|
||||||||
Net Sales Growth vs 2017 (b)
|
9.0
|
%
|
14.0
|
%
|
8.3
|
%
|
12.3
|
%
|
||||||||
Diluted EPS (b) (c)
|
$
|
0.40
|
$
|
0.50
|
$
|
1.95
|
$
|
2.15
|
||||||||
Adjusted Diluted EPS (b) (c) (d)
|
$
|
0.58
|
$
|
0.68
|
$
|
2.60
|
$
|
2.80
|
||||||||
Cap Ex ($ millions)
|
$
|
30.0
|
$
|
40.0
|
$
|
100.0
|
$
|
120.0
|
||||||||
Effective Tax Rate (b) (c)
|
35.5
|
%
|
42.5
|
%
|
28.0
|
%
|
33.0
|
%
|
||||||||
Adjusted Effective Tax Rate (b) (c) (d)
|
27.5
|
%
|
34.5
|
%
|
22.0
|
%
|
27.0
|
%
|
||||||||
(a) Management is evaluating our current approach to assigning and maintaining Volume Point values for certain products or markets. Guidance excludes any future potential impact of Volume Point adjustments, which may have an impact on the use of Volume Points as a proxy for sales trends in future periods.
(b) Excludes any future potential Venezuela currency devaluations and associated pricing and inflationary consequences.
(c) Excludes the following items that cannot be accurately predicted: any future potential ongoing tax effects from the exercise of equity awards that could impact the Company's tax rate due to the updated stock compensation accounting standard, any future contingent value rights revaluation, benefits from future potential China grant income, any future potential dilution from the Company’s convertible notes due in 2019 and 2024, as well as any impact of the China Growth and Impact Investment Program.
(d) Adjusted diluted EPS and adjusted effective tax rate excludes the impact of: non-cash interest expense associated with the Company’s convertible notes, expenses related to regulatory inquiries, China grant income, contingent value rights revaluation, loss on extinguishment of convertible debt, and Venezuela currency devaluation, as detailed in Schedule A. See Schedule A – “Reconciliation of Non-GAAP Financial Measures” for a detailed reconciliation of adjusted diluted EPS to diluted EPS calculated in accordance with GAAP and a discussion of why the Company believe these non-GAAP measures are useful.
|
▪
|
With respect to guidance, the Company cannot accurately predict the impact to its share base from any future repurchases in 2018 and are therefore excluded from the guidance table above.
|
▪
|
Guidance is based on the average daily exchange rates during the first two weeks of July 2018.
|
▪
|
Adjusted1 diluted EPS guidance for the third quarter 2018 includes a projected currency headwind of approximately $0.04 per diluted share versus the third quarter of 2017.
|
▪
|
Full year 2018 adjusted1 diluted EPS guidance is approximately neutral on a constant currency basis compared to 2017, which is $0.13 lower than the benefit included in the full year 2018 guidance provided on May 3, 2018.
|
▪
|
our relationship with, and our ability to influence the actions of, our Members;
|
▪
|
improper action by our employees or Members in violation of applicable law;
|
▪
|
adverse publicity associated with our products or network marketing organization, including our ability to comfort the marketplace and regulators regarding our compliance with applicable laws;
|
▪
|
changing consumer preferences and demands;
|
▪
|
the competitive nature of our business;
|
▪
|
regulatory matters governing our products, including potential governmental or regulatory actions concerning the safety or efficacy of our products and network marketing program, including the direct selling markets in which we operate;
|
▪
|
legal challenges to our network marketing program;
|
▪
|
the consent order entered into with the FTC, the effects thereof and any failure to comply therewith;
|
▪
|
risks associated with operating internationally and the effect of economic factors, including foreign exchange, inflation, disruptions or conflicts with our third-party importers, pricing and currency devaluation risks, especially in countries such as Venezuela;
|
▪
|
uncertainties relating to interpretation and enforcement of legislation in China governing direct selling and anti-pyramiding;
|
▪
|
our inability to obtain the necessary licenses to expand our direct selling business in China;
|
▪
|
adverse changes in the Chinese economy;
|
▪
|
our dependence on increased penetration of existing markets;
|
▪
|
any material disruption to our business caused by natural disasters, other catastrophic events, acts of war or terrorism, or cyber-security incidents;
|
▪
|
contractual limitations on our ability to expand our business;
|
▪
|
our reliance on our information technology infrastructure and outside manufacturers;
|
▪
|
the sufficiency of our trademarks and other intellectual property rights;
|
▪
|
product concentration;
|
▪
|
our reliance upon, or the loss or departure of any member of, our senior management team which could negatively impact our Member relations and operating results;
|
▪
|
U.S. and foreign laws and regulations applicable to our international operations;
|
▪
|
uncertainties relating to the United Kingdom’s vote to exit from the European Union;
|
▪
|
restrictions imposed by covenants in our credit facility;
|
▪
|
risks related to the convertible notes;
|
▪
|
uncertainties relating to the application of transfer pricing, duties, value added taxes, and other tax regulations, and changes thereto;
|
▪
|
changes in tax laws, treaties or regulations, or their interpretation;
|
▪
|
taxation relating to our Members;
|
▪
|
product liability claims;
|
▪
|
our incorporation under the laws of the Cayman Islands;
|
▪
|
whether we will purchase any of our shares in the open markets or otherwise; and
|
▪
|
share price volatility related to, among other things, speculative trading and certain traders shorting our common shares.
|
Herbalife Nutrition Ltd. and Subsidiaries
|
||||||||||||||||
Condensed Consolidated Statements of Income
|
||||||||||||||||
(In millions, except per share amounts)
|
||||||||||||||||
(Unaudited)
|
||||||||||||||||
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
6/30/2018
|
6/30/2017
|
6/30/2018
|
6/30/2017
|
|||||||||||||
North America
|
$
|
262.5
|
$
|
218.4
|
$
|
493.7
|
$
|
448.2
|
||||||||
EMEA
|
260.0
|
224.7
|
508.2
|
434.5
|
||||||||||||
Asia Pacific
|
253.0
|
235.5
|
498.6
|
455.3
|
||||||||||||
Mexico
|
118.2
|
115.6
|
232.2
|
220.4
|
||||||||||||
China
|
286.8
|
242.7
|
499.0
|
458.2
|
||||||||||||
South and Central America
|
105.0
|
110.0
|
230.7
|
232.4
|
||||||||||||
Worldwide Net Sales
|
1,285.5
|
1,146.9
|
2,462.4
|
2,249.0
|
||||||||||||
Cost of Sales
|
235.4
|
218.8
|
475.3
|
423.4
|
||||||||||||
Gross Profit
|
1,050.1
|
928.1
|
1,987.1
|
1,825.6
|
||||||||||||
Royalty Overrides
|
349.8
|
318.9
|
687.1
|
634.0
|
||||||||||||
Selling, General and Administrative Expenses
|
510.2
|
443.2
|
970.3
|
881.8
|
||||||||||||
Other Operating Income (1)
|
(1.7
|
)
|
(38.9
|
)
|
(17.9
|
)
|
(38.9
|
)
|
||||||||
Operating Income
|
191.8
|
204.9
|
347.6
|
348.7
|
||||||||||||
Interest Expense, net
|
44.3
|
37.9
|
84.2
|
68.1
|
||||||||||||
Other Expense, net (2)
|
4.7
|
-
|
29.1
|
-
|
||||||||||||
Income Before Income Taxes
|
142.8
|
167.0
|
234.3
|
280.6
|
||||||||||||
Income Taxes (3)
|
48.4
|
29.4
|
57.8
|
57.8
|
||||||||||||
Net Income
|
$
|
94.4
|
$
|
137.6
|
$
|
176.5
|
$
|
222.8
|
||||||||
Weighted Average Shares Outstanding:
|
||||||||||||||||
Basic
|
142.3
|
162.9
|
144.0
|
164.6
|
||||||||||||
Diluted
|
151.9
|
170.6
|
153.0
|
172.1
|
||||||||||||
Earnings Per Share:
|
||||||||||||||||
Basic
|
$
|
0.66
|
$
|
0.84
|
$
|
1.23
|
$
|
1.35
|
||||||||
Diluted
|
$
|
0.62
|
$
|
0.81
|
$
|
1.15
|
$
|
1.30
|
||||||||
(1) Other Operating Income relates to certain China government grant income.
|
||||||||||||||||
(2) Other Expense for the three months ended June 30, 2018 relates to the loss on revaluation of the Contingent Value Rights (CVR) issued in connection with the October 2017 modified Dutch auction tender offer. Other Expense for the six months ended June 30, 2018 loss on the extinguishment of a portion of the 2.0% convertible senior notes due 2019 repurchased in March 2018 and the loss on revaluation of the CVR.
|
||||||||||||||||
(3) Includes the impact of excess tax benefit recognized under ASU 2016-09 of $10.9 million and $21.4 million for the three months ended June 30, 2018 and 2017, respectively; and $30.2 million and $25.7 million for the six months ended June 30, 2018 and 2017, respectively
|
Herbalife Nutrition Ltd. and Subsidiaries
|
||||||||
Condensed Consolidated Balance Sheets
|
||||||||
(In millions)
|
||||||||
(Unaudited)
|
||||||||
Jun 30,
|
Dec 31,
|
|||||||
2018
|
2017
|
|||||||
ASSETS
|
||||||||
Current Assets:
|
||||||||
Cash and cash equivalents
|
$
|
839.4
|
$
|
1,278.8
|
||||
Receivables, net
|
100.0
|
93.3
|
||||||
Inventories
|
315.1
|
341.2
|
||||||
Prepaid expenses and other current assets
|
181.8
|
147.0
|
||||||
Total Current Assets
|
1,436.3
|
1,860.3
|
||||||
Property, plant and equipment, net
|
355.9
|
377.5
|
||||||
Marketing related intangibles and other intangible assets, net
|
310.1
|
310.1
|
||||||
Goodwill
|
93.5
|
96.9
|
||||||
Other assets
|
225.7
|
250.3
|
||||||
Total Assets
|
$
|
2,421.5
|
$
|
2,895.1
|
||||
LIABILITIES AND SHAREHOLDERS' DEFICIT
|
||||||||
Current Liabilities:
|
||||||||
Accounts payable
|
$
|
83.9
|
$
|
67.8
|
||||
Royalty overrides
|
255.7
|
277.7
|
||||||
Current portion of long-term debt
|
744.3
|
102.4
|
||||||
Other current liabilities
|
486.3
|
458.9
|
||||||
Total Current Liabilities
|
1,570.2
|
906.8
|
||||||
Non-current liabilities
|
||||||||
Long-term debt, net of current portion
|
1,456.4
|
2,165.7
|
||||||
Other non-current liabilities
|
174.3
|
157.3
|
||||||
Total Liabilities
|
3,200.9
|
3,229.8
|
||||||
Commitments and Contingencies
|
||||||||
Shareholders' deficit:
|
||||||||
Common shares
|
0.1
|
0.1
|
||||||
Paid-in capital in excess of par value
|
389.4
|
407.3
|
||||||
Accumulated other comprehensive loss
|
(193.6
|
)
|
(165.4
|
)
|
||||
Accumulated deficit
|
(646.4
|
)
|
(248.1
|
)
|
||||
Treasury stock
|
(328.9
|
)
|
(328.6
|
)
|
||||
Total Shareholders' Deficit
|
(779.4
|
)
|
(334.7
|
)
|
||||
Total Liabilities and Shareholders' Deficit
|
$
|
2,421.5
|
$
|
2,895.1
|
||||
Herbalife Nutrition Ltd. and Subsidiaries
|
||||||||
Condensed Consolidated Statements of Cash Flows
|
||||||||
(In millions)
|
||||||||
(Unaudited)
|
||||||||
Six Months Ended
|
||||||||
6/30/2018
|
6/30/2017
|
|||||||
CASH FLOWS FROM OPERATING ACTIVITIES:
|
||||||||
Net income
|
$
|
176.5
|
$
|
222.8
|
||||
Adjustments to reconcile net income to net cash provided by
|
||||||||
operating activities:
|
||||||||
Depreciation and amortization
|
50.8
|
48.6
|
||||||
Share-based compensation expenses
|
20.2
|
22.7
|
||||||
Non-cash interest expense
|
34.4
|
29.5
|
||||||
Deferred income taxes
|
2.0
|
0.7
|
||||||
Inventory write-downs
|
13.2
|
11.2
|
||||||
Foreign exchange transaction loss
|
3.9
|
0.9
|
||||||
Other
|
29.9
|
(3.3
|
)
|
|||||
Changes in operating assets and liabilities:
|
||||||||
Receivables
|
(21.8
|
)
|
(17.8
|
)
|
||||
Inventories
|
(2.0
|
)
|
5.2
|
|||||
Prepaid expenses and other current assets
|
(29.9
|
)
|
6.0
|
|||||
Accounts payable
|
23.8
|
10.3
|
||||||
Royalty overrides
|
(7.9
|
)
|
(23.3
|
)
|
||||
Other current liabilities
|
46.5
|
(48.7
|
)
|
|||||
Other
|
5.3
|
12.3
|
||||||
NET CASH PROVIDED BY OPERATING ACTIVITIES
|
344.9
|
277.1
|
||||||
CASH FLOWS FROM INVESTING ACTIVITIES:
|
||||||||
Purchases of property, plant and equipment
|
(33.0
|
)
|
(45.9
|
)
|
||||
Other
|
-
|
0.3
|
||||||
NET CASH USED IN INVESTING ACTIVITIES
|
(33.0
|
)
|
(45.6
|
)
|
||||
CASH FLOWS FROM FINANCING ACTIVITIES:
|
||||||||
Borrowings from senior secured credit facility, net of discount
|
-
|
1,274.0
|
||||||
Principal payments on senior secured credit facility and other debt
|
(49.0
|
)
|
(441.3
|
)
|
||||
Proceeds from convertible senior notes
|
550.0
|
-
|
||||||
Repurchase of convertible senior notes
|
(582.5
|
)
|
-
|
|||||
Debt issuance costs
|
(12.5
|
)
|
(22.6
|
)
|
||||
Share repurchases
|
(685.6
|
)
|
(273.6
|
)
|
||||
Proceeds from settlement of capped call transactions
|
55.9
|
-
|
||||||
Other
|
1.1
|
1.0
|
||||||
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES
|
(722.6
|
)
|
537.5
|
|||||
EFFECT OF EXCHANGE RATE CHANGES ON CASH, CASH EQUIVALENTS, AND RESTRICTED CASH
|
(29.7
|
)
|
13.4
|
|||||
NET CHANGE IN CASH, CASH EQUIVALENTS, AND RESTRICTED CASH
|
(440.4
|
)
|
782.4
|
|||||
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, BEGINNING OF PERIOD
|
1,295.5
|
857.0
|
||||||
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, END OF PERIOD
|
$
|
855.1
|
$
|
1,639.4
|
||||
The following is a reconciliation of net income, presented and reported in accordance with U.S. generally accepted accounting principles, to net income adjusted for certain items:
|
||||||||||||||||
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
6/30/2018
|
6/30/2017
|
6/30/2018
|
6/30/2017
|
|||||||||||||
(in million)
|
||||||||||||||||
Net income, as reported
|
$
|
94.4
|
$
|
137.6
|
$
|
176.5
|
$
|
222.8
|
||||||||
Expenses incurred responding to attacks on the Company's business model (1) (2)
|
-
|
1.6
|
-
|
3.1
|
||||||||||||
Expenses related to regulatory inquiries (1) (2)
|
2.0
|
2.9
|
4.3
|
6.7
|
||||||||||||
Non-cash interest expense and amortization of non-cash issuance costs (1) (2) (3)
|
15.6
|
11.8
|
28.1
|
23.5
|
||||||||||||
China grant income (1) (2)
|
(1.7
|
)
|
(38.9
|
)
|
(17.9
|
)
|
(38.9
|
)
|
||||||||
FTC Consent Order implementation (1) (2) (4)
|
-
|
5.2
|
-
|
13.7
|
||||||||||||
Contingent Value Rights revaluation (1) (2)
|
4.7
|
-
|
16.0
|
-
|
||||||||||||
Loss on extinguishment of convertible debt (1) (2) (5)
|
-
|
-
|
13.1
|
-
|
||||||||||||
Venezuela devaluation (1) (2)
|
-
|
-
|
4.7
|
-
|
||||||||||||
Income tax adjustments for above items (1) (2)
|
4.6
|
8.9
|
1.3
|
5.4
|
||||||||||||
Net income, as adjusted (6)
|
$
|
119.5
|
$
|
129.1
|
$
|
226.0
|
$
|
236.3
|
||||||||
The following table is a reconciliation of diluted shares outstanding, as presented and reported in accordance with GAAP, to adjusted diluted shares outstanding, adjusted to include the impact of outstanding capped call transactions. The Company's outstanding capped call transactions are anti-dilutive and not included in GAAP earnings per share but are expected to mitigate the dilutive effect of the Company's convertible notes due 2019, if the trading price of the Company's stock exceeds the conversion price, up to a certain level. Therefore, the Company has adjusted the diluted shares outstanding to include the impact of the capped calls, based on the average share price for the period that the capped calls are anti-dilutive.
|
||||||||||||||||
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
6/30/2018
|
6/30/2017
|
6/30/2018
|
6/30/2017
|
|||||||||||||
(in millions)
|
||||||||||||||||
Diluted shares outstanding, as reported
|
151.9
|
170.6
|
153.0
|
172.1
|
||||||||||||
Impact of capped call transactions
|
(2.8
|
)
|
-
|
(1.9
|
)
|
-
|
||||||||||
Diluted shares outstanding, as adjusted
|
149.1
|
170.6
|
151.1
|
172.1
|
||||||||||||
The following is a reconciliation of diluted earnings per share, presented and reported in accordance with U.S. generally accepted accounting principles, to diluted earnings per share adjusted for certain items.
|
||||||||||||||||
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
6/30/2018
|
6/30/2017
|
6/30/2018
|
6/30/2017
|
|||||||||||||
(per share)
|
||||||||||||||||
Diluted earnings per share, as reported
|
$
|
0.62
|
$
|
0.81
|
$
|
1.15
|
$
|
1.30
|
||||||||
Impact of adjusted shares outstanding
|
0.01
|
-
|
0.01
|
-
|
||||||||||||
Diluted earnings per share using adjusted diluted shares outstanding
|
$
|
0.63
|
$
|
0.81
|
$
|
1.16
|
$
|
1.30
|
||||||||
Expenses incurred responding to attacks on the Company's business model (1) (2)
|
-
|
0.01
|
-
|
0.02
|
||||||||||||
Expenses related to regulatory inquiries (1) (2)
|
0.01
|
0.02
|
0.03
|
0.04
|
||||||||||||
Non-cash interest expense and amortization of non-cash issuance costs (1) (2) (3)
|
0.10
|
0.07
|
0.19
|
0.14
|
||||||||||||
China grant income (1) (2)
|
(0.01
|
)
|
(0.23
|
)
|
(0.12
|
)
|
(0.23
|
)
|
||||||||
FTC Consent Order implementation (1) (2) (4)
|
-
|
0.03
|
-
|
0.08
|
||||||||||||
Contingent Value Rights revaluation (1) (2)
|
0.03
|
-
|
0.11
|
-
|
||||||||||||
Loss on extinguishment of convertible debt (1) (2) (5)
|
-
|
-
|
0.09
|
-
|
||||||||||||
Venezuela devaluation (1) (2)
|
-
|
-
|
0.03
|
-
|
||||||||||||
Income tax adjustments for above items (1) (2)
|
0.03
|
0.05
|
0.01
|
0.03
|
||||||||||||
Diluted earnings per share, as adjusted (6)
|
$
|
0.80
|
$
|
0.76
|
$
|
1.50
|
$
|
1.37
|
||||||||
(1) Based on interim income tax reporting rules, these expenses are not considered discrete items. As a result, the Company's full year effective tax rate is impacted by these items. When applying the full year effective tax rate to year-to-date income, the Company's year-to-date tax provision recorded with respect to these non-GAAP adjustments is different from the forecasted full-year tax provision impact of these items. As a consequence, adjustments to the year-to-date and quarterly tax impacts will be recorded as the adjusted full year effective tax rate is applied to income in subsequent periods. Additionally, adjustments to items unrelated to these non-GAAP adjustments may have an effect on the income tax impact of these non-GAAP adjustments in subsequent periods. The Company plans to update the income tax impact of these items in subsequent interim reporting periods.
|
||||||||||||||||
(2) Excludes tax (benefit)/expense as follows:
|
||||||||||||||||
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
6/30/2018
|
6/30/2017
|
6/30/2018
|
6/30/2017
|
|||||||||||||
(in millions)
|
||||||||||||||||
Expenses incurred responding to attacks on the Company's business model
|
$
|
-
|
$
|
(0.4
|
)
|
$
|
-
|
$
|
(0.8
|
)
|
||||||
Expenses related to regulatory inquiries
|
0.6
|
(0.9
|
)
|
0.4
|
(2.2
|
)
|
||||||||||
Non-cash interest expense and amortization of non-cash issuance costs
|
1.4
|
0.8
|
1.1
|
1.8
|
||||||||||||
China grant income
|
0.3
|
11.1
|
6.1
|
11.1
|
||||||||||||
FTC Consent Order implementation
|
-
|
(1.7
|
)
|
-
|
(4.5
|
)
|
||||||||||
Contingent Value Rights revaluation
|
0.5
|
-
|
(2.8
|
)
|
-
|
|||||||||||
Loss on extinguishment of convertible debt
|
1.6
|
-
|
(2.1
|
)
|
-
|
|||||||||||
Venezuela devaluation
|
0.2
|
-
|
(1.4
|
)
|
-
|
|||||||||||
Total income tax adjustments
|
$
|
4.6
|
$
|
8.9
|
$
|
1.3
|
$
|
5.4
|
||||||||
Three Months Ended
|
Six Months Ended
|
|||||||||||||||
6/30/2018
|
6/30/2017
|
6/30/2018
|
6/30/2017
|
|||||||||||||
(per share)
|
||||||||||||||||
Expenses incurred responding to attacks on the Company's business model
|
$
|
-
|
$
|
-
|
$
|
-
|
$
|
(0.01
|
)
|
|||||||
Expenses related to regulatory inquiries
|
-
|
(0.01
|
)
|
-
|
(0.02
|
)
|
||||||||||
Non-cash interest expense and amortization of non-cash issuance costs
|
0.01
|
0.01
|
0.01
|
0.01
|
||||||||||||
China grant income
|
-
|
0.07
|
0.04
|
0.07
|
||||||||||||
FTC Consent Order Implementation
|
-
|
(0.01
|
)
|
-
|
(0.03
|
)
|
||||||||||
Contingent Value Rights revaluation
|
-
|
-
|
(0.02
|
)
|
-
|
|||||||||||
Loss on extinguishment of convertible debt
|
0.01
|
-
|
(0.01
|
)
|
-
|
|||||||||||
Venezuela devaluation
|
-
|
-
|
(0.01
|
)
|
-
|
|||||||||||
Total income tax adjustments (6)
|
$
|
0.03
|
$
|
0.05
|
$
|
0.01
|
$
|
0.03
|
||||||||
(3) Relates to non-cash expense on the Company's 2.00% convertible senior notes due 2019 and the related prepaid forward share repurchase contract and the 2.625% convertible senior notes due 2024.
|
||||||||||||||||
(4) Includes $3.0 million of product discounts related to preferred member conversions for the six months ended June 30, 2017.
|
||||||||||||||||
(5) Relates to the loss on the extinguishment of a portion of the 2.00% convertible senior notes due 2019 repurchased in March 2018.
|
||||||||||||||||
(6) Amounts may not total due to rounding.
|
The following is a reconciliation of diluted earnings per share guidance, presented in accordance with U.S. generally accepted accounting principles, to adjusted diluted earnings per share guidance for certain items.
|
||||||||
Three Months Ending
|
Twelve Months Ending
|
|||||||
September 30, 2018
|
December 31, 2018
|
|||||||
Diluted EPS Guidance (1)
|
$
|
0.40 - $0.50
|
$
|
1.95 - $2.15
|
||||
Non-cash interest expense and amortization of non-cash issuance costs (2)
|
0.09
|
0.36
|
||||||
Expenses related to regulatory inquiries (3)
|
0.03
|
0.08
|
||||||
China Grant Income (4)
|
-
|
(0.12
|
)
|
|||||
Contingent value rights revaluation (5)
|
-
|
0.11
|
||||||
Loss on extinguishment of convertible debt (6)
|
-
|
0.09
|
||||||
Venezuela devaluation (7)
|
-
|
0.03
|
||||||
Impact of adjusted shares outstanding
|
0.01
|
0.03
|
||||||
Income tax adjustments for above items (8)
|
0.04
|
0.05
|
||||||
Adjusted Diluted EPS Guidance (9)
|
$
|
0.58 - $0.68
|
$
|
2.60 - $2.80
|
||||
(1) Excludes the potential ongoing tax effects from the exercise of equity awards that will impact our tax rate beginning fiscal year 2017 due to a recently issued Stock Compensation accounting standard.
|
||||||||
(2) Relates to non-cash expense on our convertible notes and prepaid forward share repurchase contract. Excludes tax impact of $0.6 million for the three months ending September 30, 2018.
|
||||||||
(3) Excludes tax impact of $0.7 million and $1.1 million for the three months ending September 30, 2018 and the twelve months ending December 31, 2018, respectively.
|
||||||||
(4) Excludes tax impact of $0.5 million and $5.1 million for the three months ending September 30, 2018 and the twelve months ending December 31, 2018, respectively.
|
||||||||
(5) Excludes tax impact of $1.4 million for the three months ending September 30, 2018.
|
||||||||
(6) Excludes tax impact of $1.1 million for the three months ending September 30, 2018.
|
||||||||
(7) Excludes tax impact of $0.2 million and $1.0 million for the three months ending September 30, 2018 and the twelve months ending December 31, 2018, respectively.
|
||||||||
(8) Aggregates the individual tax impacts of each item as described in greater detail in footnotes 3 through 7 above.
|
||||||||
(9) Amounts may not total due to rounding.
|
||||||||